Whenever possible, deferral until the patient is less contagious can be considered.33, 69, 73 3 MANAGEMENT Prophylaxis and medical management Adequate anticoagulation in COVID-19 patients appears to correlate with better outcomes in severe COVID-19 infections and a lower incidence of PE. 17, 74 However, acute PE and breakthrough PEs occur in severely ill hospitalised COVID-19 patients despite prophylactic or therapeutic anticoagulation.9, 13 - 15, 23, 75 Recent studies investigating PE in COVID-19 patients indicate that statin therapy may be beneficial in decreasing the risk of PE, 9, 19 although definite studies are needed to validate this observation.76 The International Society on Thrombosis and Haemostasis and the American Society of Hematology recommend all hospitalised patients with COVID-19 receive pharmacologic thromboprophylaxis, with standard-dose low molecular weight heparin or unfractionated heparin injections and if there are contraindications, using other measures such as pneumatic compression devices.75 Therapeutic (full-dose) anticoagulation in patients with COVID-19 is reserved for patients with confirmed VTE.